SMOC2 promotes microglia activity and neuroinflammation in Alzheimer's disease
Journal of Alzheimer’s Disease · 2025-02 · 103 (3) · 941-950
DOI: 10.1177/13872877241307337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 10.01.2025. Verfasst von Tianchi Wan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Microglia, Alzheimer Disease, Calcium-Binding Proteins, Neuroinflammatory Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Background
Alzheimer's disease (AD), the leading cause of dementia, is characterized by cognitive decline and the accumulation of amyloid-β (Aβ). It affects millions, with numbers expected to double by 2050. SMOC2, implicated in inflammation and fibrosis, may play a role in AD pathogenesis, particularly in microglial cell function, offering a potential therapeutic target.
Objective
Alzheimer's disease (AD) leads to neurodegeneration, affecting cognition, language, and personality, underscoring the urgency for effective treatments. Our study investigates the role of secreted modular calcium-binding protein 2 (SMOC2) in microglial cells and its impact on AD pathology.
Methods
We introduced SMOC2 overexpression and interference vectors into microglial cells treated with Aβ. Activity and phagocytosis were assessed using CCK8 and flow cytometry. SMOC2 mRNA levels were quantified by qPCR, and protein levels of SMOC2, TGF-β1, p-NF-κB/NF-κB were analyzed by western blot. Aβ content was determined by ELISA, and immunofluorescence detected TNF-α, IL-1β, CD163, and CD206.
Results
Aβ treatment inhibited microglial activity and phagocytosis, but SMOC2 disruption enhanced these functions (p < 0.05). SMOC2 overexpression increased its expression and Aβ levels, while interference reduced them (p < 0.001). SMOC2 overexpression also decreased TGF-β1, CD163, and CD206, and increased p-NF-κB/NF-κB, TNF-α, and IL-1β (p < 0.05).
Conclusions
SMOC2 plays a crucial role in microglial cell activity, phagocytosis, and polarization, potentially through the TGF-β1/NF-κB pathway, offering insights into AD pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Vascular Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
ORCID-Profile: Tianchi Wan, Chunkai Wang
Zitieren
APA
Wan, T., & Wang, C. (2025). SMOC2 promotes microglia activity and neuroinflammation in Alzheimer's disease. Journal of Alzheimer’s Disease, 103(3), 941-950. https://doi.org/10.1177/13872877241307337
Vancouver
Wan T, Wang C. SMOC2 promotes microglia activity and neuroinflammation in Alzheimer's disease. Journal of Alzheimer’s Disease. 2025;103(3):941-950. doi:10.1177/13872877241307337
BibTeX
@article{Wan2025,
author = {Wan, Tianchi and Wang, Chunkai},
title = {SMOC2 promotes microglia activity and neuroinflammation in Alzheimer's disease},
journal = {Journal of Alzheimer’s Disease},
year = {2025},
volume = {103},
number = {3},
pages = {941--950},
doi = {10.1177/13872877241307337}
}
EUVIMED